Literature DB >> 25806302

Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations.

Tetsuya Mitsudomi1.   

Abstract

Lung cancer is a leading cause of cancer-related mortality in many countries. Although recent advances in targeted therapy against driver oncogenes have significantly improved patient outcome, cure of this disease is still exceptional. Although tobacco is a known cause of lung cancer, not all smokers develop lung cancer, and conversely many patients, especially Asian female patients with lung cancer, are lifetime never-smokers. Therefore, efforts to understand the basis for different susceptibilities to lung cancer among individuals with different genetic, biologic, ethnic, and social backgrounds are important to help develop effective preventive measures. Lung cancer in never-smokers has many different characteristics to lung cancer in smokers, such as adenocarcinoma predominance and high frequency of epidermal growth factor receptor (EGFR) mutation yet low number of genetic changes. Epidemiologic studies suggest that East Asians are more susceptible to smoking-unrelated lung cancer but less susceptible to smoking-related lung cancer compared with Caucasians. Mutations in the EGFR gene are more common in Asian females and never-smokers. Our case-control study suggests that EGFR mutation occurs independent of smoking, and that the apparent low frequency of EGFR mutations in smokers may be the result of dilution by smoking-related lung cancer. The frequencies of three EGFR gene polymorphisms associated with increased protein expression are significantly different between East Asians and Caucasians, favoring lower protein expression in East Asians. Although these may be associated with preferred expression of the EGFR mutant allele, it is difficult to explain the frequent EGFR mutation in Asian patients. Genome wide association studies (GWAS) revealed several loci related to lung cancer susceptibility. In the future, GWAS may identify loci that are specifically related to EGFR-targeted carcinogenesis, leading to identification of carcinogens that induce EGFR mutations and effective prevention measures.

Entities:  

Keywords:  Susceptibility; adenocarcinoma; ethnic difference; genome wide association studies (GWAS); never smokers; tobacco smoke

Year:  2014        PMID: 25806302      PMCID: PMC4367697          DOI: 10.3978/j.issn.2218-6751.2014.08.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  25 in total

1.  Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression.

Authors:  H Buerger; F Gebhardt; H Schmidt; A Beckmann; K Hutmacher; R Simon; R Lelle; W Boecker; B Brandt
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

2.  Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese.

Authors:  Keitaro Matsuo; Hidemi Ito; Yasushi Yatabe; Akio Hiraki; Kaoru Hirose; Kenji Wakai; Takayuki Kosaka; Takeshi Suzuki; Kazuo Tajima; Tetsuya Mitsudomi
Journal:  Cancer Sci       Date:  2007-01       Impact factor: 6.716

3.  A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.

Authors:  Wanqing Liu; Federico Innocenti; Michael H Wu; Apurva A Desai; M Eileen Dolan; Edwin H Cook; Mark J Ratain
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

4.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

Authors:  Antonio Marchetti; Carla Martella; Lara Felicioni; Fabio Barassi; Simona Salvatore; Antonio Chella; Pier P Camplese; Teodorico Iarussi; Felice Mucilli; Andrea Mezzetti; Franco Cuccurullo; Rocco Sacco; Fiamma Buttitta
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

Review 5.  The biology and treatment of EML4-ALK non-small cell lung cancer.

Authors:  Takaaki Sasaki; Scott J Rodig; Lucian R Chirieac; Pasi A Jänne
Journal:  Eur J Cancer       Date:  2010-04-24       Impact factor: 9.162

6.  Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type.

Authors:  H A Risch; G R Howe; M Jain; J D Burch; E J Holowaty; A B Miller
Journal:  Am J Epidemiol       Date:  1993-09-01       Impact factor: 4.897

Review 7.  Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.

Authors:  Tetsuya Mitsudomi; Yasushi Yatabe
Journal:  Cancer Sci       Date:  2007-09-20       Impact factor: 6.716

Review 8.  Genetic susceptibility to lung cancer and co-morbidities.

Authors:  Ian A Yang; John W Holloway; Kwun M Fong
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

9.  Differences in lung cancer risk between men and women: examination of the evidence.

Authors:  E A Zang; E L Wynder
Journal:  J Natl Cancer Inst       Date:  1996-02-21       Impact factor: 13.506

10.  Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies.

Authors:  Michael J Thun; Lindsay M Hannan; Lucile L Adams-Campbell; Paolo Boffetta; Julie E Buring; Diane Feskanich; W Dana Flanders; Sun Ha Jee; Kota Katanoda; Laurence N Kolonel; I-Min Lee; Tomomi Marugame; Julie R Palmer; Elio Riboli; Tomotaka Sobue; Erika Avila-Tang; Lynne R Wilkens; Jon M Samet
Journal:  PLoS Med       Date:  2008-09-09       Impact factor: 11.069

View more
  30 in total

1.  FAM13A is associated with non-small cell lung cancer (NSCLC) progression and controls tumor cell proliferation and survival.

Authors:  Felix Eisenhut; Lisanne Heim; Sonja Trump; Susanne Mittler; Nina Sopel; Katerina Andreev; Fulvia Ferrazzi; Arif B Ekici; Ralf Rieker; Rebekka Springel; Vera L Assmann; Matthias Lechmann; Sonja Koch; Marina Engelhardt; Christina Warnecke; Denis I Trufa; Horia Sirbu; Arndt Hartmann; Susetta Finotto
Journal:  Oncoimmunology       Date:  2016-12-14       Impact factor: 8.110

2.  Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

Authors:  Mark J McKeage; Dusan Kotasek; Ben Markman; Manuel Hidalgo; Michael J Millward; Michael B Jameson; Dean L Harris; Robert J Stagg; Ann M Kapoun; Lu Xu; Brett G M Hughes
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

3.  Exon 7 splicing variant of estrogen receptor α is associated with pathological invasiveness in smoking-independent lung adenocarcinoma.

Authors:  Ayumi Suzuki; Katsuhiro Okuda; Motoki Yano; Risa Oda; Tadashi Sakane; Osamu Kawano; Hiroshi Haneda; Satoru Moriyama; Makoto Nakanishi; Ryoichi Nakanishi
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

4.  CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway.

Authors:  Zhipeng Tang; Wendan Yu; Changlin Zhang; Shilei Zhao; Zhenlong Yu; Xiangsheng Xiao; Ranran Tang; Yang Xuan; Wenjing Yang; Jiaojiao Hao; Tingting Xu; Qianyi Zhang; Wenlin Huang; Wuguo Deng; Wei Guo
Journal:  Mol Oncol       Date:  2015-11-05       Impact factor: 6.603

5.  Molecular alterations in a new cell line (KU-Lu-MPPt3) established from a human lung adenocarcinoma with a micropapillary pattern.

Authors:  Yukiko Matsuo; Kazu Shiomi; Dai Sonoda; Masashi Mikubo; Masahito Naito; Yoshio Matsui; Tsutomu Yoshida; Yukitoshi Satoh
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-01       Impact factor: 4.553

6.  Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis.

Authors:  Evangelos Tsiambas; Nicholas S Mastronikolis; Alicia Y Lefas; Stavros N Georgiannos; Vasileios Ragos; Panagiotis P Fotiades; Nikolaos Tsoukalas; Nikolaos Kavantzas; Andreas Karameris; Dimitrios Peschos; Efstratios Patsouris; Konstantinos Syrigos
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

7.  Inverse correlation between galectin-4 and TTF-1 in lung adenocarcinoma.

Authors:  Kieko Hara; Tsuyoshi Saito; Takuo Hayashi; Keiko Mitani; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki; Takashi Yao
Journal:  Virchows Arch       Date:  2017-07-19       Impact factor: 4.064

Review 8.  Management of Dermatologic Complications of Lung Cancer Therapies.

Authors:  Silvina B Pugliese; Joel W Neal; Bernice Y Kwong
Journal:  Curr Treat Options Oncol       Date:  2015-10

9.  Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer.

Authors:  Evgeny N Imyanitov; Irina A Demidova; Marat G Gordiev; Maxim L Filipenko; Tatyana V Kekeyeva; Yuri K Moliaka; Polina A Gervas; Valeriy B Kozhemyako; Dmitriy I Vodolazhskiy; Liubov A Sergeyeva; Dinara U Fattakhova; Aglaya G Iyevleva; Natalia V Mitiushkina; Ekatherina Sh Kuligina; Alexey A Barinov; Meriiam S Mommaeva; Svetlana N Aleksakhina; Ilya V Tsimafeyeu; Sergey A Tjulandin
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

Review 10.  Lung cancer in never smokers-the East Asian experience.

Authors:  Fei Zhou; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2018-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.